Blood test may predict which lung cancer patients respond to immunotherapy

NCT ID NCT04790682

Recruiting now Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing whether a liquid biopsy (a blood test that looks for tumor DNA) can predict how well immunotherapy works in people with advanced lung cancer. Researchers will track changes in ctDNA levels from before treatment to six weeks after, and see if those changes match tumor shrinkage on scans. The goal is to find a quick, non-invasive way to tell if the treatment is working, so patients can get the most effective care sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liquid biopsy (ctDNA testing)
What this could lead to: If successful, this could help doctors quickly identify which lung cancer patients will benefit from immunotherapy, avoiding ineffective treatments.
What could go wrong: This is an observational study, not a treatment trial. The test may not accurately predict responses, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC LUNG CANCER

Contacts and locations

Locations

Hopital Ambroise Pare
RECRUITING

Boulogne-Billancourt, 92100, France
Institut Curie
RECRUITING

Paris, 75005, France
Institut Curie
RECRUITING

Saint-Cloud, 92210, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.